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Purpose: To evaluate the functional and anatomic outcomes of photodynamic therapy (PDT) for choroidal 
neovascularization (CNV) in patients with angioid streaks. 
Methods: The authors retrospectively evaluated 6 consecutive patients (6 eyes) with CNV secondary to 
angioid streaks. All patients were treated with standard PDT with verteporfin protocol. Standardized protocol 
refraction, visual acuity testing, ophthalmologic examination, color photographs, fluorescein angiograms and 
indocyanin angiograms were used to evaluate the results of PDT with verteporfin. Main outcome measures 
were visual acuity and CNV size. 
Results: Their mean age was 61.3±5.50 years (range, 53-68 years). Follow-up time ranged from 12 to 38 
months with mean of 20.5±10.91 months. The mean visual acuity at baseline was 20/100 (range 
20/25-20/500), and the mean visual acuity at the last examination was 20/320(range 20/125-counting finger). 
The mean greatest linear dimension (GLD) at baseline was 2400±766.81 µm, and the mean GLD at the 
last examination was 3483±444.59 µm. 
Conclusions: PDT for CNV associated with angioid streaks seemed to slow down but not prevent the 
progression of the disease and associated visual loss.
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Angioid streaks represent dehiscences in Bruch's 
membrane and are associated with various systemic diseases 
such as pseudoxanthoma elasticum, Ehler-Danlos syndrome, 
Paget disease, and various blood dyscrasias.
1 Choroidal 
neovascularization (CNV) is the major cause of vision loss 
associated with angioid streaks. Although data on the natural 
history of CNV associated with angioid streaks is poor, 
historical surveys report that CNV occurs in 70% to 86% of 
patients during follow-up, with most eyes progressing to legal 
blindness.
2,3 Although conventional laser photocoagulation for 
juxtafoveal and extrafoveal choroidal neovascularization 
secondary to angioid streaks may mitigate the rate of visual 
loss, treatment modalities for subfoveal neovascularization 
remain limited.
4-6 Recently, photodynamic therapy (PDT) 
with verteporfin has been introduced as a treatment for 
reducing visual loss in patients with CNV due to age-related 
macular degeneration, pathologic myopia.
7,8 Unlike conventional 
laser photocoagulation, PDT can close CNV with minimal or 
no detectable damage to the surrounding tissues. Therefore, 
it allows the clinician to treat subfoveal CNV without 
immediately adversely affecting central visual function. The 
purpose of this study was to determine the functional and 
anatomic results of PDT in patients with subfoveal CNV 
related to angioid streaks.
Materials and Methods
A retrospective analysis of 6 eyes of 6 patients diagnosed 
with subfoveal choroidal neovascularization associated with 
angioid streaks and treated by the authors from October 2003 
through december 2006 was conducted. The diagnosis of 
angioid streaks was based on the typical clinical and 
angiographic appearance of bilateral broad, irregular, reddish 
brown or gray lines that radiate from the area around the 
optic nerve head. Patients with fundus abnormalities 
associated with other ocular diseases that can cause CNV, 
such as age-related drusen, were not included in the study. 
All patients underwent color photography, fluorescein and 
indocyanine green angiography, and complete ocular 
examinations with determination of best-corrected visual JK Chang, et al. SOLITARY FIBROFOLLICULOMA
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Case Age Sex Eye F/U Basaline VA Final VA 1 years VA Baseline GLD
* Final GLD
* No. of PDT
1 66 M OD 12 Mon 20/100 20/125 20/125 3200 3700 2
2 58 F OD 12 Mon 20/500 20/200 20/200 2500 2900 2
3 63 F OD 14 Mon 20/25 20/100 20/125 1600 3000 1
4 53 F OS 30 Mon 20/125 C. F
† 20/160 3400 4000 2
5 60 M OS 17 Mon 20/125 20/800 20/500 2000 3500 1
6 68 F OD 38 Mon 20/100 C. F
† C. F
† 1700 3800 2
GLD
* : greatest linear dimension.
C. F
†: counting finger.
Table 1. Patient characteristics and course of therapy after PDT in 6 patients with CNV associated with angioid 
streaks
acuity both before treatment and at all subsequent follow-up 
visits. Main outcome measures were visual acuity and CNV 
size. Visual acuity was measured using an Early Treatment 
of Diabetic Retinopathy Study chart and was approximated 
to the nearest Snellen equivalent. The greatest linear 
dimension (GLD) was measured including all lesion 
components. Photodynamic therapy was administered using 
the same procedure as in the Treatment of Age-related 
Macular Degeneration with Photodynamic Therapy (TAP) 
and Verteporfin in Photodynamic Therapy (VIP) studies.
7,8 
Verteporfin (Visudyne; Novartis Ophthalmic AG, Hettlinger 
Switzerland) is reconstituted with sterile water and diluted 
with 5% dextrose to achieve a drug dose of 6 mg/m
2  body 
surface area (BSA) and a total infusion volume of 30 ml. The 
solution is infused intravenously at a rate of 3 ml/min over 
10 minutes. Laser (Coherent, Palo Alto, California, USA) 
application is carried out at 15 minutes after the start of the 
infusion. The spot size is determined by measuring the 
greatest linear dimension of the entire lesion and an 
additional 1000 µm is added to this value. The time to deliver 
50 J/cm
2 laser dose is 83 seconds. The patients were 
instructed to avoid direct sunlight or bright indoor light for 
48 h after treatment. Retreatments were considered when 
active leakage was observed at 3 month intervals.
Results
Three patients were men and three patients were women. 
Their mean age was 61.3±5.50 years (range, 53-68 years.) 
In four cases the right eye was affected and in two cases, 
the left eye. Follow-up time ranged from 12 to 38 months 
with mean of 20.5±10.91 months. Four patients were treated 
twice and two patients were treated once (Table 1). The mean 
visual acuity at baseline was 20/100 (range 20/25-20/500), 
and the mean visual acuity at the last examination was 
20/320 (range 20/125-counting finger). Visual acuity of 
counting fingers was assigned a value of 20/2000. The mean 
GLD at baseline was 2400±766.81 µm, and the mean GLD 
at the last examination was 3483±444.59 µm. The mean line 
change was -4.0 lines (ETDRS charts). One patient improved 
visual acuity. No unexpected ocular or systemic adverse 
events were noted in either patient group.
Discussion
The natural prognosis of CNV in angioid streaks has been 
reported to be unfavorable insofar as most eyes become 
legally blind by 1 years.
1-3 Different therapeutic approaches 
have been used in the attempt to treat this vision-threatening 
disease. Laser photocoagulation has not yielded good 
results.
4-6 This treatment was indicated in non-subfoveal 
lesions, but frequently the centre of the fovea was finally 
affected due to relapse of the initial lesion or enlargement of 
the laser scar.
PDT with verteporfin can reduce vision loss in the more 
common type of CNV, such as age-related macular 
degeneration and pathologic myopia.
7,8 Thus, PDT with 
verteporfin has been tested in the treatment of CNV 
secondary to angioid streaks. The first published case reports 
and series of PDT in patients with angioid streaks seemed 
to be particularly promising. Sickenberg et al.
9 documented 
no visual loss in a 52-year-old male patient with 3-month 
follow-up. Karacorlu et al.
10 described eight cases with 
subfoveal CNV and a mean follow-up of 8 months. The 
results were quite good, with stabilization or improvement of 
visual acuity in all cases. In contrast to these reports, recently 
published series report somewhat less encouraging results of 
PDT for CNV associated with angioid streaks.
12-16 Shaikh et 
al.
12 described an increased in lesion size in seven out of nine 
CNV treated with multiple sessions. In the largest series 
published to date, Menchini et al.
11 combined the results of 
48 eyes out of six centers in Italy. With a minimum 
follow-up of 12 months, they found a decrease in visual 
acuity in 32% of patients with subfoveal lesions and in 50% 
in patients with extra- or juxtafoveal CNV. Overall, 18% had 
a visual acuity <20/200 at the final examination, and a 62% 
the lesion size determined by GLD measurements increased 
comparing baseline to final examination. Browning et al.
13 
described that PDT might limit the visual loss in the majority 
of patients through the first 12 months of follow-up.
In our study, treated CNV initially displayed a stabilization 
of visual acuity (defined as visual loss<3 lines) following 
PDT. Stabilization of visual acuity was achieved in four 
patients through the 12 months of follow-up. Visual 
improvement was obtained in one patient. The mean line Kor J Ophthalmol Vol.21, No.3, 2007
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Fig. 1. Case 5 : Pretreatment fundus photography (A) and fluorescein angiogram (B) reveals subfoveal choroidal neovascular 
membrane associated with hemorrhage. Posttreatment fundus photography (C) and fluorescein angiogram (D) at 9 months reveal 
marked enlargement, increased leakage, and disciform conversion of the neovascular complex
change was -4.1 lines (ETDRS charts). Changes in GLD had 
a tendency to enlarge despite receiving PDT (Figure 1). The 
mean GLD at baseline was 2400±766.81 µm, and the mean 
GLD at the last examination was 3483±444.59 µm. In our 
experience PDT with verteporfin does not seem to be a good 
treatment to stabilize visual acuity and lesion size in CNV 
secondary to angioid streaks. However, compared to the 
aggressive natural course and to the limited treatment options, 
PDT may at least in part help to stabilize macular function 
over a limited period of time. We think that PDT should be 
considered in selected cases until better therapeutic modalities 
become available. In the future, modifications of the PDT 
treatment may have the potential to further improve the visual 
outcome in this population. As the combination of PDT with 
intravitreal triamcinolone acetonide showed promising results 
in a group of patients that did initially not show a good 
response to PDT treatment,
17 and combinations of PDT with 
anti-angiogenic substances are currently investigated in 
clinical studies.
18 We think that these combinations merit 
further investigation and might possibly enhance the results 
of the PDT treatment of patients with CNV and angioid 
streaks.
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